24/7 Market News Snapshot 09 October, 2025 – Alterity Therapeutics Limited American Depositary Shares (NASDAQ:ATHE)

October 9, 2025

DENVER, Colo., 09 October, 2025 (www.247marketnews.com) – (NASDAQ:ATHE) are discussed in this article.
Alterity Therapeutics Limited has garnered significant attention as its stock surged 21.11% in pre-market trading, reaching $5.22. This notable rise follows the positive sentiment surrounding the company’s recent advancements in developing treatments for neurodegenerative diseases, specifically Multiple System Atrophy (MSA). The current trading volume of 1.50 million shares suggests a robust interest from investors, indicative of rising confidence in Alterity’s potential.

The spike in share price coincides with the presentation of pivotal findings from the Phase 2 clinical trial of ATH434, Alterity’s lead candidate. Showcased at the 2025 International Congress of Parkinson’s Disease and Movement Disorders, the trial results highlight ATH434’s ability to slow the progression of MSA, a disease characterized by debilitating symptoms and limited treatment options. According to Dr. David Stamler, CEO of Alterity, the data from the ATH434-201 trial strengthens the belief that ATH434 could serve as a transformative therapy for patients facing this challenging condition.

The randomized, double-blind trial provided compelling data, particularly at the 75 mg dosage, demonstrating efficacy in stabilizing orthostatic hypotension—a troubling symptom associated with MSA—over a 52-week period. Furthermore, advanced neuroimaging and biomarker techniques employed during the trial not only improved diagnostic precision for MSA but also facilitated a detailed assessment of disease progression across different clinical phenotypes.

The findings affirm Alterity’s commitment to enhancing treatment options for MSA while pursuing innovative strategies that integrate disease biomarkers and neuroimaging techniques. As the company progresses, these developments signal a significant step toward redefining approaches in managing neurodegenerative disorders, ultimately providing new hope for affected patients and their families.

Related news for (ATHE)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.